KR20040012426A - 인간 유래 β-디펜신 타입 2 및/또는 타입 3의 유도활성성분 및 상기 활성성분을 포함하는 화장품 또는약학적 조성물 - Google Patents
인간 유래 β-디펜신 타입 2 및/또는 타입 3의 유도활성성분 및 상기 활성성분을 포함하는 화장품 또는약학적 조성물 Download PDFInfo
- Publication number
- KR20040012426A KR20040012426A KR1020020077561A KR20020077561A KR20040012426A KR 20040012426 A KR20040012426 A KR 20040012426A KR 1020020077561 A KR1020020077561 A KR 1020020077561A KR 20020077561 A KR20020077561 A KR 20020077561A KR 20040012426 A KR20040012426 A KR 20040012426A
- Authority
- KR
- South Korea
- Prior art keywords
- type
- active ingredient
- defensin
- expression
- hbd2
- Prior art date
Links
- 239000004480 active ingredient Substances 0.000 title claims abstract description 102
- 102000012265 beta-defensin Human genes 0.000 title claims abstract description 58
- 108050002883 beta-defensin Proteins 0.000 title claims abstract description 58
- 239000002537 cosmetic Substances 0.000 title claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 230000004936 stimulating effect Effects 0.000 title description 7
- 230000014509 gene expression Effects 0.000 claims abstract description 59
- 230000001939 inductive effect Effects 0.000 claims abstract description 40
- 230000006698 induction Effects 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 238000006243 chemical reaction Methods 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 65
- 239000000126 substance Substances 0.000 claims description 52
- 230000004054 inflammatory process Effects 0.000 claims description 47
- 230000000770 proinflammatory effect Effects 0.000 claims description 35
- 102000007469 Actins Human genes 0.000 claims description 34
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 33
- 210000003491 skin Anatomy 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 30
- 102000000541 Defensins Human genes 0.000 claims description 28
- 108010002069 Defensins Proteins 0.000 claims description 28
- 108010085238 Actins Proteins 0.000 claims description 25
- 230000015572 biosynthetic process Effects 0.000 claims description 25
- 238000003786 synthesis reaction Methods 0.000 claims description 25
- 238000012216 screening Methods 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 238000003757 reverse transcription PCR Methods 0.000 claims description 23
- 239000013543 active substance Substances 0.000 claims description 22
- ZNJFBWYDHIGLCU-HWKXXFMVSA-N jasmonic acid Chemical compound CC\C=C/C[C@@H]1[C@@H](CC(O)=O)CCC1=O ZNJFBWYDHIGLCU-HWKXXFMVSA-N 0.000 claims description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 241000282412 Homo Species 0.000 claims description 21
- 210000002510 keratinocyte Anatomy 0.000 claims description 21
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 20
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 17
- 230000003321 amplification Effects 0.000 claims description 17
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 claims description 16
- 206010020751 Hypersensitivity Diseases 0.000 claims description 15
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 claims description 15
- 101710200814 Melanotropin alpha Proteins 0.000 claims description 15
- 208000026935 allergic disease Diseases 0.000 claims description 15
- 210000002919 epithelial cell Anatomy 0.000 claims description 15
- 230000009610 hypersensitivity Effects 0.000 claims description 15
- 239000000047 product Substances 0.000 claims description 14
- 108020004999 messenger RNA Proteins 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 13
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 12
- 239000011575 calcium Substances 0.000 claims description 12
- 229910052791 calcium Inorganic materials 0.000 claims description 12
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 12
- 238000013334 tissue model Methods 0.000 claims description 12
- 241000208983 Arnica Species 0.000 claims description 11
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 11
- 240000006162 Chenopodium quinoa Species 0.000 claims description 11
- 206010061218 Inflammation Diseases 0.000 claims description 11
- ZNJFBWYDHIGLCU-UHFFFAOYSA-N jasmonic acid Natural products CCC=CCC1C(CC(O)=O)CCC1=O ZNJFBWYDHIGLCU-UHFFFAOYSA-N 0.000 claims description 11
- 239000013641 positive control Substances 0.000 claims description 11
- 210000001519 tissue Anatomy 0.000 claims description 11
- 230000000844 anti-bacterial effect Effects 0.000 claims description 10
- 244000080767 Areca catechu Species 0.000 claims description 9
- 235000006226 Areca catechu Nutrition 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000000813 microbial effect Effects 0.000 claims description 9
- 239000002243 precursor Substances 0.000 claims description 9
- 240000006891 Artemisia vulgaris Species 0.000 claims description 8
- 235000000832 Ayote Nutrition 0.000 claims description 8
- 235000009854 Cucurbita moschata Nutrition 0.000 claims description 8
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 claims description 8
- 235000003222 Helianthus annuus Nutrition 0.000 claims description 8
- 235000005206 Hibiscus Nutrition 0.000 claims description 8
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 claims description 8
- 244000246386 Mentha pulegium Species 0.000 claims description 8
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 8
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 8
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 8
- 235000009470 Theobroma cacao Nutrition 0.000 claims description 8
- 244000299461 Theobroma cacao Species 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 235000001050 hortel pimenta Nutrition 0.000 claims description 8
- 235000013997 pineapple juice Nutrition 0.000 claims description 8
- 235000015136 pumpkin Nutrition 0.000 claims description 8
- 210000004761 scalp Anatomy 0.000 claims description 8
- 240000007049 Juglans regia Species 0.000 claims description 7
- 235000009496 Juglans regia Nutrition 0.000 claims description 7
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 7
- 229960000310 isoleucine Drugs 0.000 claims description 7
- -1 isoleucine ester Chemical class 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 210000004400 mucous membrane Anatomy 0.000 claims description 7
- 235000019155 vitamin A Nutrition 0.000 claims description 7
- 239000011719 vitamin A Substances 0.000 claims description 7
- 229940045997 vitamin a Drugs 0.000 claims description 7
- 235000020234 walnut Nutrition 0.000 claims description 7
- 240000002493 Smilax officinalis Species 0.000 claims description 6
- 235000008981 Smilax officinalis Nutrition 0.000 claims description 6
- 239000011543 agarose gel Substances 0.000 claims description 6
- 159000000007 calcium salts Chemical class 0.000 claims description 6
- 150000002519 isoleucine derivatives Chemical class 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 244000284380 Hibiscus rosa sinensis Species 0.000 claims description 5
- 240000001307 Myosotis scorpioides Species 0.000 claims description 5
- 235000016791 Nymphaea odorata subsp odorata Nutrition 0.000 claims description 5
- 235000003283 Pachira macrocarpa Nutrition 0.000 claims description 5
- 240000001085 Trapa natans Species 0.000 claims description 5
- 235000014364 Trapa natans Nutrition 0.000 claims description 5
- 230000000855 fungicidal effect Effects 0.000 claims description 5
- 210000004209 hair Anatomy 0.000 claims description 5
- 210000000282 nail Anatomy 0.000 claims description 5
- 235000009165 saligot Nutrition 0.000 claims description 5
- 238000010187 selection method Methods 0.000 claims description 5
- 238000007390 skin biopsy Methods 0.000 claims description 5
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 4
- 241000219122 Cucurbita Species 0.000 claims description 4
- 208000001840 Dandruff Diseases 0.000 claims description 4
- 241000208818 Helianthus Species 0.000 claims description 4
- 244000020551 Helianthus annuus Species 0.000 claims description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 4
- 241000209477 Nymphaeaceae Species 0.000 claims description 4
- 241000736199 Paeonia Species 0.000 claims description 4
- 244000170916 Paeonia officinalis Species 0.000 claims description 4
- 206010000496 acne Diseases 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 230000003641 microbiacidal effect Effects 0.000 claims description 4
- 229940124561 microbicide Drugs 0.000 claims description 4
- 239000002855 microbicide agent Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 240000008025 Alternanthera ficoidea Species 0.000 claims description 3
- 240000004244 Cucurbita moschata Species 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 102000001400 Tryptase Human genes 0.000 claims description 2
- 108060005989 Tryptase Proteins 0.000 claims description 2
- 229940037003 alum Drugs 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 229960001340 histamine Drugs 0.000 claims description 2
- 150000002617 leukotrienes Chemical class 0.000 claims description 2
- 230000003278 mimic effect Effects 0.000 claims description 2
- 150000003180 prostaglandins Chemical class 0.000 claims description 2
- 239000012679 serum free medium Substances 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 208000015898 Bacterial Skin disease Diseases 0.000 claims 1
- 208000007163 Dermatomycoses Diseases 0.000 claims 1
- 206010012504 Dermatophytosis Diseases 0.000 claims 1
- 235000010254 Jasminum officinale Nutrition 0.000 claims 1
- 240000005385 Jasminum sambac Species 0.000 claims 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 claims 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 claims 1
- 241000209490 Nymphaea Species 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 230000003334 potential effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 abstract description 15
- 230000007794 irritation Effects 0.000 abstract description 3
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 description 60
- 102000049262 human DEFB4A Human genes 0.000 description 60
- 101000912247 Homo sapiens Beta-defensin 103 Proteins 0.000 description 58
- 102000055779 human DEFB103A Human genes 0.000 description 57
- 102000004890 Interleukin-8 Human genes 0.000 description 19
- 108090001007 Interleukin-8 Proteins 0.000 description 19
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 14
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 14
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 14
- 239000000463 material Substances 0.000 description 10
- 101000756632 Homo sapiens Actin, cytoplasmic 1 Proteins 0.000 description 9
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 7
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 7
- 229940067596 butylparaben Drugs 0.000 description 7
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 7
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 7
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 7
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 7
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 7
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 7
- 229960002216 methylparaben Drugs 0.000 description 7
- 229960005323 phenoxyethanol Drugs 0.000 description 7
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 7
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 7
- 229960003415 propylparaben Drugs 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- 229930182844 L-isoleucine Natural products 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 5
- 239000002386 air freshener Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 229940008099 dimethicone Drugs 0.000 description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 description 5
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 5
- 229960003471 retinol Drugs 0.000 description 5
- 235000020944 retinol Nutrition 0.000 description 5
- 239000011607 retinol Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000002356 single layer Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 229940075529 glyceryl stearate Drugs 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 229930002330 retinoic acid Natural products 0.000 description 4
- 229960001727 tretinoin Drugs 0.000 description 4
- 229940075420 xanthine Drugs 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 3
- 235000003097 Artemisia absinthium Nutrition 0.000 description 3
- 240000001851 Artemisia dracunculus Species 0.000 description 3
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241001070941 Castanea Species 0.000 description 3
- 235000014036 Castanea Nutrition 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 241000218033 Hibiscus Species 0.000 description 3
- 101000952040 Homo sapiens Beta-defensin 1 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000001138 artemisia absinthium Substances 0.000 description 3
- 229960001631 carbomer Drugs 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 102000046975 human DEFB1 Human genes 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 3
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 2
- 241000269350 Anura Species 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 101710178508 Defensin 3 Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 235000010676 Ocimum basilicum Nutrition 0.000 description 2
- 240000007926 Ocimum gratissimum Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 235000011034 Rubus glaucus Nutrition 0.000 description 2
- 244000235659 Rubus idaeus Species 0.000 description 2
- 235000009122 Rubus idaeus Nutrition 0.000 description 2
- 241000239226 Scorpiones Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 102000018568 alpha-Defensin Human genes 0.000 description 2
- 108050007802 alpha-defensin Proteins 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 235000020279 black tea Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 2
- YXMMTUJDQTVJEN-WDSKDSINSA-N methyl (2s,3s)-2-amino-3-methylpentanoate Chemical compound CC[C@H](C)[C@H](N)C(=O)OC YXMMTUJDQTVJEN-WDSKDSINSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229920002189 poly(glycerol 1-O-monomethacrylate) polymer Polymers 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 210000002105 tongue Anatomy 0.000 description 2
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- OVYMWJFNQQOJBU-UHFFFAOYSA-N 1-octanoyloxypropan-2-yl octanoate Chemical compound CCCCCCCC(=O)OCC(C)OC(=O)CCCCCCC OVYMWJFNQQOJBU-UHFFFAOYSA-N 0.000 description 1
- DGSZGZSCHSQXFV-UHFFFAOYSA-N 2,3-bis(2-ethylhexanoyloxy)propyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(OC(=O)C(CC)CCCC)COC(=O)C(CC)CCCC DGSZGZSCHSQXFV-UHFFFAOYSA-N 0.000 description 1
- NFIHXTUNNGIYRF-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate Chemical compound CCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCC NFIHXTUNNGIYRF-UHFFFAOYSA-N 0.000 description 1
- XULHFMYCBKQGEE-UHFFFAOYSA-N 2-hexyl-1-Decanol Chemical compound CCCCCCCCC(CO)CCCCCC XULHFMYCBKQGEE-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 102100026887 Beta-defensin 103 Human genes 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- GVXLTVRLYLNKDB-UHFFFAOYSA-N CC(O)CO.OCCOC1=CC=CC=C1 Chemical compound CC(O)CO.OCCOC1=CC=CC=C1 GVXLTVRLYLNKDB-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241001331167 Caulolatilus affinis Species 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 101710178510 Defensin-2 Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 241001113556 Elodea Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010017543 Fungal skin infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010055171 Hypertensive nephropathy Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001147138 Mytilus galloprovincialis Species 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 101100274508 Oryza sativa subsp. japonica CKI1 gene Proteins 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010052891 Skin bacterial infection Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000255588 Tephritidae Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical group 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- TVWTZAGVNBPXHU-NXVVXOECSA-N dioctyl (z)-but-2-enedioate Chemical compound CCCCCCCCOC(=O)\C=C/C(=O)OCCCCCCCC TVWTZAGVNBPXHU-NXVVXOECSA-N 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000026721 nail disease Diseases 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- HMMGMWAXVFQUOA-UHFFFAOYSA-N octamethylcyclotetrasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 HMMGMWAXVFQUOA-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical group OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/49—Fagaceae (Beech family), e.g. oak or chestnut
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/12—Face or body powders for grooming, adorning or absorbing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/70—Biological properties of the composition as a whole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/75—Anti-irritant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
Description
활성물질(1% 사용, w/w) | hBD2 | MIP3α | IL8 |
대조군 | 0% | 6.7 | 30.9 |
TNFα | 100% | 33 | 186 |
스피룰린(spirulin) | 137% | 28.8 | 87 |
퀴노아 가루 | 85% | - | - |
쑥 뿌리 | 76% | 7.2 | 30.2 |
딱총나무 껍질 | 65% | 7.5 | 17.9 |
해바라기 | 58% | 10.9 | 68.6 |
망초 | 50% | 6.1 | 29.4 |
파인애플 주스 | 50% | 7.6 | 39 |
럽춰워트 | 44% | 7.8 | 55 |
코코아 | 39% | 4.9 | 22.5+ |
호박 | 35% | 5.2 | 33.1 |
페퍼민트 | 26% | 1 | 4.8 |
사르사팔리아 뿌리 | 26% | 4.7 | 15.4 |
빈랑나무 | 1% | 0 | 25.7 |
아르니카 꽃 | 0% | 3.9 | 27.8 |
모란 꽃 | 0% | 0 | 2 |
물레나물 | 0% | 2.81 | 19.37 |
밤나무 | 0% | 0.6 | 36.7 |
볼도 | 0% | 1.8 | 20.1 |
호두나무 잎 | 0% | 1.4 | 19.4 |
히비스커스 꽃 | 0% | 6.5 | 29.3 |
바질 잎 | 0% | - | - |
홍차 | 0% | - | - |
나무딸기 | 0% | - | - |
L-이소루신 10㎍/mL | 0% | - | - |
D,L-이소루신 100 ㎍/mL | 0% | 5.6 | 30.6 |
이소루신 메틸 에스테르 100 ㎍/mL | 16% | 3.8 | 7.7 |
자스몬산 100 ㎍/mL | 7% | 6 | 25.3 |
활성물질(1% 사용, w/w) | hBD2 | MIP3α | IL8 |
대조군 | 0% | 6.7 | 30.9 |
TNFα | 100% | 13.8 | 97 |
아르니카 꽃 | 460% | 3.9 | 27.8 |
모란 꽃 | 192% | 0 | 2 |
물레나물 | 126% | 2.81 | 19.7 |
밤나무 | 103% | 0.6 | 36.7 |
볼도 | 86% | 1.8 | 20.1 |
럽춰워트 | 73% | 7.8 | 55 |
히비스커스 꽃 | 50% | 6.5 | 29.3 |
빈랑나무 | 45% | 0 | 25.7 |
페퍼민트 | 40% | 1 | 4.8 |
호두나무 잎 | 27% | 1.4 | 19.4 |
코코아 | 15% | 4.9 | 22.5 |
스피룰린 | 6% | 28.8 | 87 |
바질 잎 | 0% | - | - |
홍차 | 0% | - | - |
나무딸기 | 0% | - | - |
쑥 뿌리 | 0% | 7.2 | 30.2 |
망초 | 0% | 6.1 | 29.4 |
딱총나무 껍질 | 0% | 7.5 | 17.9 |
파인애플 주스 | 0% | 7.6 | 39 |
퀴노아 가루 | 0% | 8 | 39 |
사르사파릴라 뿌리 | 0% | 4.7 | 15.4 |
해바라기 | 0% | 10.9 | 68.6 |
호박 | 0% | 5.2 | 33.1 |
L-이소루신 10㎍/mL | 0% | - | - |
D,L-이소루신 100 ㎍/mL | 0% | 5.6 | 30.6 |
이소루신 메틸 에스테르 100 ㎍/mL | 6% | 3.8 | 7.7 |
자스몬산 100 ㎍/mL | 0% | 6 | 25.3 |
활성성분 | 농도 | 생존능 | hBD2 | hBD3 | MIP3α | IL8 | IL1α |
대조군 | 100% | 100% | 100% | 5.6 | 47.4 | 26.9 | |
TNFα | 100 ng/mL | - | 1755% | 774% | 23.6 | 175 | 21.8 |
IFNγ | 100 ng/mL | - | 472% | 4631% | 11.6 | 100.5 | 40.1 |
볼도 | 0.1%0.5%1% | 84%87%76% | 182%92%72% | 168%213%703% | 2.21.450.4 | 33.627.531.7 | 28.225.320.2 |
아르니카 | 0.01%0.1%0.3% | 93%91%75% | 117%128%138% | 173%561%1830% | 4.62.54.1 | 51.234.124.1 | 30.138.537.9 |
퀴노아 | 0.1%1%5%10% | 83%91%90%92% | 143%264%401%92% | 102%112%237%438% | 65.812.47.6 | 58.750.2150.2102.8 | 23.417.734.440.8 |
쑥 | 0.1%1%5%10% | 87%75%78%83% | 88%117%130%104% | 103%116%452%3962% | 3.22.93.22.3 | 36.93561.666.3 | 39.534.922.325.8 |
빈랑나무 | 0.1%1%2% | 87%77%70% | 88%35%98% | 84%261%2781% | 2.80.280 | 32.223.77.6 | 28.339.544.8 |
L-이소루신 ㎍/mL | 3.1256.2512.525 | ---- | 110%107%95%110% | 89%94%101%106% | 5.24.95.94.5 | 36.933.642.235.1 | 2122.325.322.8 |
자스몬산 ㎍/mL | 100500 | -- | 86%134% | 477%26919% | 4.613.6 | 37.9103.3 | 31.297.1 |
α-MSH ng/mL | 1100 | -- | 198%186% | 254%217% | 4.53.9 | 34.641.7 | 24.726.1 |
활성물질 | 농도 | hBD2 | hBD3 |
대조군 | 100% | 100% | |
TNFα | 100 ng/mL | 1755% | 774% |
IFNγ | 100 ng/mL | 472% | 4631% |
레티노산 | 0.005% | 26% | 161% |
레티놀 | 0.01% | 168% | 17562% |
INCI 명 | 함량 |
물 | 100으로 채움 |
글리세린 | 5 |
카르보머(carbomer?) | 0.2 |
테트라소듐 EDTA | 0.1 |
차나무잎기름 | 2 |
수화된 폴리이소부텐 | 8 |
글리세릴 스테아레이트 에스이 | 2 |
디메티콘 | 1 |
글리세릴 스테아레이트 및 PEG-100 스테아레이트 | 1.5 |
트리에틸헥사노인 | 5 |
스테아르산 | 2 |
세틸 알콜 | 1 |
실리카 | 1 |
디카프릴릴 말레이트 | 6 |
글리세릴 스테아레이트 | 1 |
디메티콤 | 3.5 |
물 | 2.3 |
트리에탄올아민 | 0.5 |
페녹시에탄올, 메틸파라벤, 프로필파라벤, 부틸파라벤, 에틸파라벤 | 0.7 |
방향제 | 0.3 |
토코페롤 아세테이트 | 0.5 |
레티놀 | 0.1 |
소듐 하이알루로네이트 | 0.03 |
적성초 추출물 | 1 |
가수분해된 간장단백질 | 0.4 |
본 발명 물질 | 0.001 ~ 20 |
INCI 명 | 함량 |
물 | 100으로 채움 |
트리소듐 EDTA | 0.1 |
하이드록시메틸셀룰로오스 | 0.1 |
크산틴검 | 0.3 |
페녹시에탄올, 메틸파라벤, 프로필파라벤, 부틸파라벤, 에틸파라벤 | 0.56 |
부틸렌 글리콜 | 5 |
폴리소르베이트 20 | 1 |
방향제 | 0.05 |
토코페롤 아세테이트 | 0.1 |
소듐 시트레이트 | 0.65 |
마그네슘 아스코르빌포스페이트 | 1 |
본 발명 물질 | 0.001 ~ 20 |
INCI 명 | 함량 |
물 | 100으로 채움 |
마그네슘 알루미늄 실리케이트 | 0.5 |
셀룰로오스검 | 0.35 |
글리세린 | 3 |
폴리비닐 피롤리돈 | 5 |
디프로필렌 글리콜 | 0.05 |
프로필렌 글리콜 | 2 |
페녹시에탄올, 메틸파라벤, 프로필파라벤, 부틸파라벤, 에틸파라벤 | 1 |
크산틴검 | 0.2 |
트리에탄올아민 | 0.7 |
이소프로필 팔미테이트 | 4 |
미네랄 오일 | 2 |
헥실데카놀 | 3 |
글리세릴 스테아레이트 | 2 |
스테아르산 | 2.4 |
올레산 | 0.5 |
폴리소르베이트 80 | 0.7 |
토코페롤 | 0.5 |
티타니움 디옥사이드 | 7 |
산화철 | 4 |
나일론-2 | 6 |
소듐 하이알루로네이트 | 0.01 |
방향제 | 0.05 |
프로필렌 글리콜 디카프릴레이트/디카프레이트 | 7.2 |
본 발명 물질 | 0.001 ~ 20 |
INCI 명 | 함량 |
옥틸메톡시시나메이트 | 4 |
세틸 PEG/PPG-10/1디메티콘 | 3 |
Bis-PEG/PPG-14/14 디메티콘 | 3 |
디메티콘 | 6 |
사이클로메티콘 | 4 |
폴리데센 | 4 |
페녹시에탄올, 메틸파라벤, 프로필파라벤, 부틸파라벤, 에틸파라벤 | 0.65 |
토코페롤 | 0.5 |
방향제 | 0.8 |
PPG-3 미리스틸 에스테르 | 0.5 |
티타늄 디옥사이드 | 8 |
페녹시에탄올 | 0.35 |
소듐 시트레이트 | 0.65 |
마그네슘 아스코르빌 포스페이트 | 3 |
물 | QSP 100 |
크산틴검 | 0.4 |
부틸렌 글리콜 | 2 |
본 발명 물질 | 0.001 ~ 20 |
INCI 명 | 함량 |
물 | 100 으로 채움 |
테트라소듐 EDTA | 0.2 |
카르보머? | 0.5 |
글리세린 | 3.0 |
폴리글리세릴메타크릴레이트 및 프로필렌 글리콜 | 5.0 |
디프로필렌 글리콜 | 3.0 |
부틸렌 글리콜 | 5.0 |
페녹시에탄올, 메틸파라벤, 프로필파라벤, 부틸파라벤, 에틸파라벤 | 0.65 |
트리에탄올아민 | 0.5 |
카페인 | 2 |
루스커스 아쿠레아투스 추출물 | 1 |
본 발명 물질 | 0.001 ~ 20 |
INCI 명 | 함량 |
물 | 100 g으로 맞춤 |
카르보머? | 0.35 |
테트라소듐 EDTA | 0.1 |
폴리소르베이트 60 | 3 |
솔비탄 스테아레이트 | 2.6 |
이소프로필 팔미테이트 | 2.5 |
세틸 팔미테이트 | 4 |
에틸헥실 팔미테이트 | 5.1 |
스쿠알렌 | 1 |
세틸 알콜 | 2.5 |
사이클로메티콘 | 1 |
디메티콘 | 0.5 |
트리에탄올아민 | 0.53 |
부틸렌 글리콜 | 5 |
방향제 | 0.3 |
페녹시에탄올, 메틸파라벤, 프로필파라벤, 부틸파라벤, 에틸파라벤 | 0.65 |
토코페랄 아세테이트 | 0.5 |
소듐 하이알루로네이트 | 0.03 |
스위트 아몬드 오일 단백질 및 글리세린 | 2 |
폴리글리세릴메타크릴레이트 | 5 |
본 발명 물질 | 0.001 ~ 20 |
INCI 명 | 함량 |
물 | 100 g으로 채움 |
크산틴검 | 0.8 |
시트르산 | 0.8 |
소듐 로레트 설페이트 | 40 |
페녹시에탄올, 메틸파라벤, 프로필파라벤, 부틸파라벤, 에틸파라벤 | 2 |
본 발명 물질 | 0.001 ~ 20 |
Claims (31)
- 염증, 과민증 혹은 불내성 반응을 유발시키지 않음을 특징으로 하는 인간 유래 β-디펜신 타입 2(hBD2) 및/또는 인간 유래 β-디펜신 타입 3(hBD3)의 발현을 직접 혹은 간접적으로 유도할 수 있는 활성성분.
- 염증과정 동안 보통 함께 발현되는 친염증성 분자 혹은 물질의 직접 혹은 간접 합성을 감지할 수 있는 정도로 유도하지 않거나 혹은 자극하지 않음을 특징으로 하는 인간 유래 β-디펜신 타입 2(hBD2) 및/또는 인간 유래 β-디펜신 타입 3(hBD3)의 발현을 직접 혹은 간접적으로 유도할 수 있는 활성성분.
- 제 1항 또는 제 2항에 있어서, 염증과정 동안 보통 함께 발현되는 상기 친염증성 분자 혹은 물질은 MIP α(대식세포 염증 단백질), IL8, IL1 혹은 다른 인터루킨, 히스타민, 트립타아제, 기질 P, 류코트리엔스, 혹은 프로스타글란딘임을 특징으로 하는 활성성분.
- 제 1항 내지 제 3항 중 어느 한 항에 있어서, 상기 활성성분은 인간 유래의 상피배양세포, 특히 케라티노사이트 및/또는 각질배양세포, 생존상태의 인간피부생검, 재건표피모델 혹은 재건피부모델에서 염증과정 동안 보통 함께 발현되는 친염증성 분자 혹은 물질의 직접 혹은 간접 생성을 감지할 수 있는 정도로 유도하지 않음을 특징으로 하는 활성성분.
- 제 1항 내지 제 4항 중 어느 한 항에 있어서, 상기 활성성분은 쑥 뿌리, 망초, 딱총나무 껍질, 럽쳐워트(rupturewort), 파인애플 주스, 페퍼민트, 빈랑나무, 코코아, 퀴노아, 아르니카, 볼도, 사르사파릴라, 호두나무 잎, 히비스커스 꽃, 호박, 해바라기, 모란, 물레나물, 밤나무, 혹은 그들의 추출물, 자스몬산 혹은 비타민 A, 그것의 유도체 및 전구체, α-MSH 혹은 α-MSH를 구성하는 펩타이드 중 하나 혹은 상기 펩타이드 중 하나를 모방하는 화학 구조 즉 이소루신 에스테르, 칼슘 혹은 어떤 유기 혹은 무기 칼슘염으로부터 선택됨을 특징으로 하는 활성성분.
- 제 1항 내지 제 5항에 기재된 활성성분을 적어도 하나 포함함을 특징으로 하는 조성물.
- 제 6항에 있어서, 상기 활성성분은 중량 당 0.001% 내지 20%의 농도로, 바람직하게는 0.01% 내지 10%로 포함됨을 특징으로 하는 조성물.
- β-디펜신 타입 2 및/또는 타입 3의 발현을 유도할 수 있고 염증과정 동안 보통 함께 발현되는 적어도 하나의 친염증성 분자 혹은 물질의 직접 혹은 간접 합성을 감지할 수 있는 정도로 유도하지 않거나 혹은 자극하지 않을 수 있는 농도로 있으며, 화장품용 부형제와 함께 혼합될 수 있음을 특징으로 하는 제 1항 내지 제5항 중 어느 한 항에 기재된 적어도 하나의 활성성분이나 혹은 화장품 조성물의 제조를 위한 제 6항 내지 제 7항 중 어느 한 항에 기재된 조성물의 용도.
- β-디펜신 타입 2 및/또는 타입 3의 발현을 유도할 수 있고 염증과정 동안 보통 함께 발현되는 적어도 하나의 친염증성 분자 혹은 물질의 직접 혹은 간접 합성을 감지할 수 있는 정도로 유도하지 않거나 혹은 자극하지 않을 수 있는 농도로 있으며, 약제용 부형제와 함께 혼합될 수 있음을 특징으로 하는 제 1항 내지 제 5항 중 어느 한 항에 기재된 적어도 하나의 활성성분이나 혹은 약학적 조성물의 제조를 위한 제 6항 내지 제 7항 중 어느 한 항에 기재된 조성물의 용도.
- 화장품 혹은 약학적 조성물에 살미생물제 혹은 정미생물제를 적어도 하나 혼합함을 특징으로 하는 제 1항 내지 제 5항 중 어느 한 항에 기재된 적어도 하나의 활성성분의 용도.
- β-디펜신 타입 2 및/또는 타입 3의 발현을 유도할 수 있고 염증과정 동안 보통 함께 발현되는 적어도 하나의 친염증성 분자 혹은 물질의 직접 또는 간접 합성을 감지할 수 있는 정도로 유도하지 않거나 혹은 자극하지 않는 적어도 하나의 활성성분을 선별할 수 있는 특징을 갖는 세포 혹은 조직 모델.
- 제 11항에 있어서, 상기 세포 혹은 조직 모델은 상피세포, 예를 들어, 적절한 배양 조건 하에서 특히, 칼슘 함량이 0 ~ 100 mM인, 바람직하게는 1.7 mM의 농도에서 배양되기에 적합한 케라티노사이트를 포함함을 특징으로 하는 세포 혹은 조직 모델.
- a) 적절한 배양 조건 하에서 선별된 다양한 잠재적 활성성분을 첨가하여 세포 혹은 조직 모델을 배양하는 단계;b) 인간 유래의 β-디펜신 타입 2 및/또는 타입 3의 발현 유도의 유무를 직접 혹은 간접적으로 확인하는 단계; 및c) 염증과정 동안 보통 함께 발현되는 친염증성 분자 혹은 물질의 유도 유무를 직접 혹은 간접적으로 확인하는 단계를 포함함을 특징으로 하는 인간 유래의 β-디펜신 타입 2 및/또는 타입 3의 직접 혹은 간접 발현을 유도할 수 있고 염증과정 동안 보통 함께 발현되는 적어도 하나의 친염증성 분자 혹은 물질의 직접 또는 간접 합성을 감지할 수 있는 정도로 유도하지 않거나 혹은 자극하지 않을 수 있는 활성성분의 선별방법.
- 제 13항에 있어서, d)단계를 추가로 포함함을 특징으로 하는 활성성분의 선별방법:d) 인간 유래의 β-디펜신 타입 2 및/또는 타입 3의 직접 혹은 간접 발현을 유도할 수 있고 동시에 염증과정 동안 보통 함께 발현되는 친염증성 분자 혹은 물질의 직접 혹은 간접 합성을 감지할 수 있는 정도로 유도하지 않거나 혹은 자극하지 않을 수 있는 본 방법에서 시험된 적어도 하나의 활성성분을 선택하는 단계.
- 제 13항 또는 제 14항에 있어서, a)단계에서, 세포 혹은 조직 모델은 상피세포 혹은 생존상태의 피부생검 혹은 재건표피모델 혹은 재건피부모델을 포함하며, 상피세포는 예를 들어, 적절한 배양 조건 하에서 특히 칼슘 함량이 0 내지 100 mM로, 바람직하게는 1.7 mM의 농도에서 배양되기에 적합한 케라티노사이트 및/또는 각질세포를 포함함을 특징으로 하는 활성성분의 선별방법.
- 제 13항 내지 제 15항 중 어느 한 항에 있어서, a)단계에서, 6 내지 48시간동안, 바람직하게는 약 16시간 동안(접촉시간) 세포 혹은 조직 모델과 선별되는 다양한 잠재적 활성성분을 함께 배양함함을 특징으로 하는 활성성분의 선별방법.
- 제 13항 내지 제 16항 중 어느 한 항에 있어서, b)단계에, 총 RNA의 추출 및 분석을 포함함을 특징으로 하는 활성성분의 선별방법.
- 제 13항 내지 제 17항 중 어느 한 항에 있어서, b)단계에, 상기 인간 유래의 β-디펜신 타입 2 및/또는 타입 3를 코딩하는 mRNA의 분석을 포함함을 특징으로 하는 활성성분의 선별방법.
- 제 13항 내지 제 18항 중 어느 한 항에 있어서, b)단계에서, 액틴, hBD2 및hBD3에 대한 RT-PCR를 실시함을 포함하는 것을 특징으로 하는 활성성분의 선별방법.
- 제 13항 내지 제 19항 중 어느 한 항에 있어서, b)단계에서, 자외선 하에서 판독할 수 있는 핵산 삽입부를 포함하는 아가로오스 젤에 증폭 산물을 로딩함을 포함하는 것을 특징으로 하는 활성성분의 선별방법.
- 제 13항 내지 제 20항 중 어느 한 항에 있어서, b)단계에서, 자외선 하에서 hBD2/액틴 및 hBD3/액틴 밴드의 강도 비를 비교하는 것을 포함함을 특징으로 하는 활성성분의 선별방법.
- 제 13항 내지 제 21항 중 어느 한 항에 있어서, c)단계에서, 염증과정 동안 보통 함께 발현되는 친염증성 분자 혹은 물질을 분석하기 위해 ELISA 형 분석을 포함함을 특징으로 하는 활성성분의 선별방법.
- 제 13항 내지 제 22항 중 어느 한 항에 있어서, d)단계에서, 염증과정 동안 보통 함께 발현되는 친염증성 분자 혹은 물질의 직접 혹은 간접 합성을 자극하지 않거나 혹은 감지할 수 있는 정도로 유도함이 없이 상기 인간 유래의 β-디펜신 타입 2 및/또는 타입 3를 코딩하는 mRNA의 발현을 유도할 수 있는 적어도 하나의 활성성분을 선택하는 것을 포함함을 특징으로 하는 활성성분의 선별방법.
- 제 13항 내지 제 23항 중 어느 한 항에 있어서, IL1, IL8, MIP3α와 같은 염증과정 동안 보통 함께 발현되는 적어도 하나의 친염증성 분자 혹은 적어도 하나의 물질을 자극하지 않거나 혹은 감지할 수 있는 정도로 유도하지 않으면서 상기 인간 유래의 β-디펜신의 발현을 유도하는 활성성분을 선택하는 것을 포함함을 특징으로 하는 활성성분의 선별방법.
- 제 13항 내지 제 24항 중 어느 한 항에 있어서, 다음의 단계를 포함함을 특징으로 하는 활성성분의 선별방법:칼슘이 풍부한 무혈청 특이 배지에서, 예를 들어 무처리 대조군과 두개의 양성 대조군(hBD2에 대해서는 TNFα, hBD3에 대해서는 IFNγ)을 동시에 준비하여 단일층의 정상인간 유래의 케라노사이트와 선별되는 잠재적 활성성분이 접촉하는 단계;총 RNA를 추출한 다음, 광학현미경을 이용하여 바람직하게는 260 내지 280 nm의 파장에서 총 RNA를 분석하는 단계(이때 RNA를 희석할 수도 있음);초기 RNA(initial RNA)에서 액틴, hBD2 및 hBD3에 대한 RT-PCR을 실시하는 단계;예를 들어, 서모사이클러에서 액틴, hBD2 및 hBD3에 대해 동일한 증폭 프로그램에 따라 초기 RNA를 증폭하는 단계;hBD2, hBD3 및 액틴의 증폭 산물을 혼합하고 전하완충액과 물(2/3) 혼합액을첨가한 다음 최종용액을 미리 굳힌 아가로오스 젤에 침적시킨 후 시료를 이동시키고 자외선 하에서, 바람직하게는 암실에서 판독할 수 있는 기술을 사용하여 밴드를 확인한 다음 컴퓨터상으로 사진을 찍으며, 기초량의 디펜신의 발현이 탐지될 수 없기 때문에(무처리 대조군), hBD2/액틴 및 hBD3/액틴 밴드의 강도 비, 예를 들어 양성 대조군(hBD2에 대해서는 TNFα를, hBD3에 대해서는 IFNγ를 처리함)에서 얻은 결과와 비교하여 당해 β-디펜신의 발현 유도를 보여주는 단계.
- 제 13항 내지 제 25항 중 어느 한 항에 있어서, 다음의 단계를 추가적으로 포함함을 특징으로 하는 활성성분의 선별방법:인간 유래 β-디펜신 타입 2 및/또는 타입 3의 발현에 효과를 나타내는 선별되는 잠재적 활성성분을 선택하는 단계;활성성분에 해당하는 상등액을 시험하여 이들 활성물질의 영향 하에서 배양배지에 분비되는 MIP3α, IL1 및 IL8의 농도를 측정하는 단계; 예를 들어, 상기 농도는 서로 결과를 비교하기 위해 분석된 RNA 농도를 참조할 수 있음.
- 제 13항 내지 제 26항 중 어느 한 항에 있어서, 염증과정 동안 보통 함께 발현되는 친염증성 분자 혹은 물질의 직접 혹은 간접 합성을 자극하지 않거나 혹은 감지할 수 있는 정도로 유도하지 않으면서, 인간 유래의 β-디펜신 타입 2 및/또는 타입 3의 직접 혹은 간접 발현을 유도할 수 있는 활성성분을 동정할 수 있으며, 상기 활성성분은 쑥 뿌리, 망초, 딱총나무 껍질, 럽쳐워트, 파인애플 주스, 페퍼민트, 빈랑나무, 코코아, 퀴노아, 아르니카, 볼도, 사르사파릴라, 호두나무 잎, 히비스커스 꽃, 호박, 해바라기, 모란, 물레나물, 밤나무, 혹은 그들의 추출물, 자스몬산 혹은 비타민 A, 그것의 유도체 및 전구체, α-MSH 혹은 α-MSH를 구성하는 펩타이드 중 하나 혹은 상기 펩타이드 중 하나를 모방하는 화학 구조 즉 이소루신 에스테르, 칼슘 혹은 어떤 유기 혹은 무기 칼슘염으로부터 선택됨을 특징으로 하는 활성성분의 선별방법.
- 대상 조직, 특히 피부, 점막, 머리카락 및 손톱 혹은 두피에 대해 살균 및/또는 살진균 효과를 나타내는 화장품 조성물, 특히 두피의 경우 비듬을 예방하거나 혹은 치료하는 데 사용할 수 있는 화장품 조성물을 제조하기 위한 제 1항 내지 제 5항에 기재된 활성성분의 용도.
- 대상 조직에 대해 살균 및/또는 살진균 효과를 나타내기 위해, 특히 여드름 및 세균성 혹은 진균성 피부질환의 치료 및/또는 예방을 위해 사용되는 약학적 조성물을 제조하기 위한 제 1항 내지 제 5항에 기재된 활성성분의 용도.
- 제 29항에 있어서, 피부의 β-디펜신의 살균효과와 항미생물제의 효과를 겸하고, 특히 비듬, 여드름, 백반, 피부질환 및 다른 피부, 점막, 두피 및 머리카락 및 손톱과 같은 미생물 제제와 관련된 질환을 치료하기 위한 약학분야에서의 활성성분의 용도.
- 상피 및 재건피부의 구성 및 피부생검의 생존 시 β-디펜신의 살균효과를 이용하기 위한 조직재건분야에서의 제 1항 내지 제 5항에 기재된 활성성분의 용도.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0209905A FR2843125B1 (fr) | 2002-08-02 | 2002-08-02 | Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs |
FR02/09905 | 2002-08-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20040012426A true KR20040012426A (ko) | 2004-02-11 |
KR100697360B1 KR100697360B1 (ko) | 2007-03-20 |
Family
ID=8871555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020020077561A KR100697360B1 (ko) | 2002-08-02 | 2002-12-07 | 인간 유래 β-디펜신 타입 2 및/또는 타입 3의 유도활성성분 및 상기 활성성분을 포함하는 화장품 또는약학적 조성물 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20040091493A1 (ko) |
JP (3) | JP4824901B2 (ko) |
KR (1) | KR100697360B1 (ko) |
DE (2) | DE10262193B4 (ko) |
FR (1) | FR2843125B1 (ko) |
GB (1) | GB2391476B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102524684B1 (ko) * | 2022-09-05 | 2023-04-21 | 주식회사 래디안 | 피부의 방어 기능을 증진시키는 화장료 조성물 |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2843125B1 (fr) * | 2002-08-02 | 2012-11-16 | Coletica | Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs |
CN1852708B (zh) * | 2003-09-19 | 2010-09-22 | 大塚制药株式会社 | 人β防御素分泌促进剂 |
EP1731357A4 (en) * | 2004-02-02 | 2009-03-04 | Daihatsu Motor Co Ltd | AUTOMOTIVE SEAT |
FR2869541B1 (fr) | 2004-04-30 | 2007-12-28 | Expanscience Sa Lab | Utilisation d'une composition comprenant du d-mannoheptulose et/ou du perseitol dans le traitement et la prevention des maladies liees a une modification de l'immunite innee |
US7258878B2 (en) * | 2004-12-20 | 2007-08-21 | Kimberly-Clark Worldwide, Inc. | Anti-microbial composition and methods of use thereof |
US9284274B2 (en) | 2005-12-07 | 2016-03-15 | Ramot At Tel-Aviv University Ltd. | Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof |
EP2402321A3 (en) * | 2005-12-07 | 2012-02-29 | Ramot at Tel Aviv University, Ltd. | Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof |
IL176608A0 (en) * | 2006-06-28 | 2006-10-31 | Lycored Ltd | Compositions and methods for treating and preventing gastro esophageal reflux disease |
DE602007005664D1 (de) * | 2006-09-18 | 2010-05-12 | Seppic Sa | Verwendung eines quinoa-extrakts als kosmetisches und pharmazeutisches schlankheitsmittel und/oder als mittel zur verhinderung der formierung neuer fette im menschlichen körper |
FR2905861B1 (fr) * | 2006-09-18 | 2008-10-17 | Seppic Sa | Utilisation d'un extrait de quinoa comme actif prevenant la formation de nouvelles graisses dans le corps humain |
FR2905860B1 (fr) * | 2006-09-18 | 2008-10-17 | Seppic Sa | Utilisation d'un extrait de quinoa comme actif cosmetique et pharmaceutique amincissant |
NZ599605A (en) | 2007-02-19 | 2013-11-29 | Marinepolymer Tech Inc | Hemostatic compositions and therapeutic regimens |
FR2916634B1 (fr) * | 2007-06-01 | 2009-10-02 | Jean Noel Thorel | Association synergique vis-a-vis de la flore microbienne de l'epiderme humain et applications cosmetiques et pharmaceutiques |
FR2921254B1 (fr) * | 2007-09-21 | 2009-11-13 | Oreal | Utilisation en depigmentation d'une association d'acide jasmonique et d'acide ascorbique |
FR2929511B1 (fr) | 2008-04-02 | 2010-12-31 | Basf Beauty Care Solutions France Sas | Nouveau principe actif stimulant la proliferation et/ou l'activite des fibroblastes. |
KR100991293B1 (ko) | 2008-08-11 | 2010-11-01 | (주)바이오에프디엔씨 | 신규한 인간 베타 디펜신 유사 항균 펩타이드 및 이의 아토피 피부염 개선 소재로서의 활용 |
US8440237B2 (en) | 2009-04-27 | 2013-05-14 | Mary Kay Inc. | Botanical anti-acne formulations |
US9284252B2 (en) | 2009-06-09 | 2016-03-15 | Sepal Pharma Ltd. | Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders |
DE102009044970A1 (de) | 2009-07-23 | 2011-01-27 | Henkel Ag & Co. Kgaa | Verwendung von humanem beta-Defensin zur Beeinflussung des natürlichen Pigmentierungsprozesses |
DE102009029110A1 (de) * | 2009-09-02 | 2011-03-03 | Henkel Ag & Co. Kgaa | Antimikrobielle Formulierung |
GB0920846D0 (en) | 2009-11-27 | 2010-01-13 | Croda Int Plc | Defenin inducing agent |
FR2953722B1 (fr) | 2009-12-16 | 2012-03-09 | Expanscience Lab | Composition comprenant au moins un sucre en c7 pour le traitement de l'alopecie, pour le traitement cosmetique des phaneres, et pour le soin des cheveux, cils ou ongles |
JP2011168555A (ja) * | 2010-02-22 | 2011-09-01 | Pola Chemical Industries Inc | 鑑別方法 |
NZ602909A (en) | 2010-04-15 | 2015-01-30 | Marinepolymer Tech Inc | Anti-bacterial applications of poly -n-acetylglucosamine nanofibers |
CN103025386B (zh) * | 2010-05-24 | 2015-12-16 | 因德纳有限公司 | 用于治疗微生物感染的罗望子种子多糖 |
JP6266857B2 (ja) * | 2010-09-21 | 2018-01-24 | 共栄化学工業株式会社 | 化粧料 |
WO2012110971A2 (en) * | 2011-02-17 | 2012-08-23 | Promed Exports Pvt. Ltd. | Method and composition to retard sorption of preservatives to plastics |
CA2832859C (en) | 2011-04-15 | 2020-06-16 | Marine Polymer Technologies, Inc. | Treatment of disease with poly-n-acetylglucosamine nanofibers |
RU2453321C1 (ru) * | 2011-05-03 | 2012-06-20 | Общество с ограниченной ответственностью "ЛЕКВЕТ" (ООО "ЛЕКВЕТ") | Препарат для лечения животных с противовоспалительным и антибактериальным действиями |
US20140242093A1 (en) * | 2011-07-29 | 2014-08-28 | Fred Hutchinson Cancer Research Center | Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject |
EP2793848B1 (en) | 2011-12-19 | 2019-06-26 | Mary Kay, Inc. | Navy bean extract to whiten the skin and improve skin tone |
JP2013010796A (ja) * | 2012-10-15 | 2013-01-17 | Kao Corp | S100a8発現調節剤 |
CN102988979B (zh) * | 2012-12-13 | 2014-05-07 | 北京新华联协和药业有限责任公司 | 蒿属花粉变应原疫苗含片及其制备方法 |
US9511144B2 (en) | 2013-03-14 | 2016-12-06 | The Proctor & Gamble Company | Cosmetic compositions and methods providing enhanced penetration of skin care actives |
JP6364281B2 (ja) * | 2013-09-10 | 2018-07-25 | 花王株式会社 | 皮膚老化予防又は改善剤 |
KR101620148B1 (ko) * | 2013-12-19 | 2016-05-12 | 주식회사 바이오에프디엔씨 | 항균펩타이드 베타-디펜신 3 및 3h의 라우릭산 융합을 통한 장기지속형 유도체, 세포투과성 펩타이드 융합을 통한 피부투과형 유도체 개발과 이를 함유하는 화장료 조성물 |
FR3015898B1 (fr) | 2013-12-31 | 2016-02-05 | Virbac Sa | Composition topique comprenant des extraits de boldo et de reine des pres, destinee a un animal, et ses applications |
KR102323049B1 (ko) | 2014-03-10 | 2021-11-05 | 마리 케이 인코포레이티드 | 피부 라이트닝 조성물 |
JP6407848B2 (ja) * | 2015-01-14 | 2018-10-17 | 御木本製薬株式会社 | ディフェンシン産生促進剤、カテリシジン産生促進剤、抗菌剤 |
EP3389620B1 (en) * | 2015-12-15 | 2022-09-14 | Medicell Technologies, LLC | Stem cell stimulating compositions and methods of treating melasma |
EP3834615A1 (en) * | 2016-03-31 | 2021-06-16 | Gojo Industries, Inc. | Antimicrobial peptide stimulating sanitizing composition |
AU2017240069B2 (en) | 2016-03-31 | 2024-03-07 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
US10806769B2 (en) | 2016-03-31 | 2020-10-20 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
US11564879B2 (en) | 2016-11-23 | 2023-01-31 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
JP7138496B2 (ja) * | 2018-07-06 | 2022-09-16 | 花王株式会社 | 抗菌ペプチド発現促進剤 |
CN116251050B (zh) * | 2023-05-09 | 2023-08-01 | 四平名居红酒庄园有限公司 | 一种葡萄籽红酒面膜泥的制备方法 |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3062721A (en) * | 1957-03-20 | 1962-11-06 | Grate Lorene Grigsby | Skin care lotion |
US3961054A (en) * | 1973-01-22 | 1976-06-01 | Ciba-Geigy Corporation | Combatting dandruff with mercapto quinoline N-oxides |
LU81257A1 (fr) * | 1979-05-15 | 1980-12-16 | Oreal | Composition cosmetique pour le traitement des cheveux et de la peau,contenant un extrait de salsepareille |
ATE11217T1 (de) * | 1979-10-12 | 1985-02-15 | William James Cunliffe | Antibiotische substanzen, verfahren zu deren herstellung und deren zusammensetzungen; stamm von staphylococcus epidermidis, welcher diese antibiotische substanz produziert und deren zusammensetzungen. |
LU83173A1 (fr) * | 1981-02-27 | 1981-06-05 | Oreal | Nouvelles compositions cosmetiques pour le traitement des cheveux et de la peau contenant une poudre resultant de la pulverisation d'au moins une plante et un agent de cohesion |
HU190813B (en) * | 1982-10-07 | 1986-11-28 | Valyi,Gabriella,Hu | Process for producing cosmetic for aftertreating seborrhoeic and acneic processes |
US4581351A (en) * | 1982-11-23 | 1986-04-08 | Sutton Laboratories, Inc. | Composition of matter containing imidazolidinyl urea and pyrithione and its derivatives |
DE3319184A1 (de) | 1983-05-27 | 1984-11-29 | Henkel Kgaa | Verfahren zur abtrennung von allergenen aus arnikablueten mittels co(pfeil abwaerts)2(pfeil abwaerts)-hochdruckextraktion |
US4849214A (en) * | 1985-02-12 | 1989-07-18 | Ruiseco Mario G | Oil based scalp treatment composition |
JPS6253917A (ja) * | 1985-09-02 | 1987-03-09 | Shiseido Co Ltd | 頭髪化粧料 |
JPS62148427A (ja) * | 1985-12-23 | 1987-07-02 | Kao Corp | 皮膚外用剤 |
US5084270A (en) * | 1988-04-22 | 1992-01-28 | Revlon, Inc. | Cosmetic compositions containing N-alkoxyalkylamides |
US5093360A (en) * | 1989-04-07 | 1992-03-03 | Yu Ruey J | Retinal, derivatives and their therapeutic use |
US5053222A (en) * | 1989-06-07 | 1991-10-01 | Shiseido Company Ltd. | Hair cosmetic composition |
US6350784B1 (en) * | 1996-02-12 | 2002-02-26 | Meryl J. Squires | Antimicrobial prevention and treatment of human immunedeficiency virus and other infectious diseases |
JPH05331041A (ja) * | 1992-05-29 | 1993-12-14 | Tsuneo Nanba | 美白化粧料 |
ES2289370T3 (es) * | 1992-07-13 | 2008-02-01 | Shiseido Company, Ltd. | Composicion estabilizada para tratamiento cutaneo externo que comprende retinol. |
JPH06227960A (ja) * | 1993-02-01 | 1994-08-16 | Yakult Honsha Co Ltd | メラニン生成抑制剤および皮膚化粧料 |
FR2714602B1 (fr) * | 1993-12-30 | 1996-02-09 | Oreal | Composition antiacnéique pour le traitement simultané des couches superficielles et profondes de la peau, son utilisation. |
JP3922594B2 (ja) * | 1996-03-19 | 2007-05-30 | 株式会社ノエビア | 抗菌性低刺激化粧料 |
US6342208B1 (en) * | 1996-08-02 | 2002-01-29 | Plum Kerni Produktion A/S | Oil-in-water emulsion containing C10-C24 fatty acid derivatives for treating skin of mammals |
AUPO427596A0 (en) * | 1996-12-20 | 1997-01-23 | Cooperative Research Centre For Tropical Plant Pathology | Anti-microbial protein |
JP4309972B2 (ja) * | 1997-03-26 | 2009-08-05 | 雪印乳業株式会社 | 静菌及び抗菌剤 |
FR2765109B1 (fr) * | 1997-06-25 | 2001-02-09 | Seppic Sa | Composition comprenant un lipoaminoacide et les constituants d'un extrait de plantes riches en tanins et utilisation en cosmetique |
JP4061675B2 (ja) * | 1997-09-02 | 2008-03-19 | 王子製紙株式会社 | 天然物由来の抗菌剤 |
JPH11286496A (ja) * | 1997-12-22 | 1999-10-19 | Morinaga & Co Ltd | 抗菌ペプチド誘導及び/又は増強因子 |
US6984622B2 (en) * | 1998-03-25 | 2006-01-10 | The Regents Of The University Of California | Use of lipopolysaccharides to manage corneal infections and wounds |
AU3547499A (en) * | 1998-03-31 | 1999-10-18 | Abbott Laboratories | Bacterial or yeast extracts which stimulate the production of defensins and methods of use thereof |
CA2332961A1 (en) * | 1998-05-21 | 1999-11-25 | Michael Zasloff | A method for stimulation of defensin production by exposure to isoleucine |
JP4132351B2 (ja) * | 1999-02-10 | 2008-08-13 | 株式会社資生堂 | 抗プラスミン剤 |
US6887846B2 (en) * | 1999-03-24 | 2005-05-03 | Zengen, Inc. | Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone |
JP2000336024A (ja) * | 1999-05-27 | 2000-12-05 | Ichimaru Pharcos Co Ltd | 保湿性植物抽出物を含有する化粧料組成物 |
JP2001064192A (ja) * | 1999-08-25 | 2001-03-13 | Sunstar Inc | ランゲルハンス細胞の遊走抑制剤及び抗原提示抑制剤 |
US6333180B1 (en) * | 1999-12-21 | 2001-12-25 | International Flavors & Fragrances Inc. | Bioprocess for the high-yield production of food flavor-acceptable jasmonic acid and methyl jasmonate |
JP2001220313A (ja) * | 2000-02-09 | 2001-08-14 | Ichimaru Pharcos Co Ltd | 植物水蒸気蒸留水含有化粧料組成物 |
AU2001245726A1 (en) * | 2000-03-15 | 2001-09-24 | Genaera Corporation | A method for stimulation of defensin production |
FR2807319B1 (fr) | 2000-04-07 | 2004-10-22 | L M D | Composition cosmetique ou en tant que medicament contenant une lactone sesquiterpenique pour traiter les hematomes, et procede de traitement |
JP4814415B2 (ja) * | 2000-05-29 | 2011-11-16 | 一丸ファルコス株式会社 | 化粧料組成物 |
AU2001275208A1 (en) * | 2000-06-01 | 2001-12-11 | University Of Iowa Research Foundation | Human beta-defensin-3 (hbd-3), a highly cationic beta-defensin antimicrobial peptide |
EP1209238B1 (en) * | 2000-06-23 | 2005-10-19 | SAKAI, Takuo | Process for producing plant-origin antibacterial substance |
RU2180210C1 (ru) * | 2000-07-26 | 2002-03-10 | Закрытое акционерное общество "Компания КОРА" | Косметическое средство для ухода за волосами |
JP2002186485A (ja) * | 2000-12-22 | 2002-07-02 | Shiseido Co Ltd | エオタキシン、RANTES又はβ−ディフェンシン−2の核酸の測定方法及びそのための試薬、並びに抗炎症剤のスクリーニング方法 |
JP2002212009A (ja) * | 2001-01-18 | 2002-07-31 | Noevir Co Ltd | 抗かび剤、及びこれを含有して成る抗菌性低刺激化粧料 |
JP2002226403A (ja) * | 2001-02-01 | 2002-08-14 | Mareyoshi Sawaguchi | 口腔用及び皮膚科用剤の添加剤 |
JP2002241303A (ja) * | 2001-02-13 | 2002-08-28 | Hisamitsu Pharmaceut Co Inc | Ets転写因子又はそれをコードする遺伝子からなる上皮細胞のgm−csf、及び/又はディフェンシン蛋白質の発現調節剤。 |
DE10111288A1 (de) * | 2001-03-09 | 2002-09-12 | Wella Ag | Antischuppenmittel |
JP2002363065A (ja) * | 2001-06-04 | 2002-12-18 | Satoru Murakami | 薬草化粧石鹸及びローション |
FR2843125B1 (fr) * | 2002-08-02 | 2012-11-16 | Coletica | Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs |
-
2002
- 2002-08-02 FR FR0209905A patent/FR2843125B1/fr not_active Expired - Fee Related
- 2002-11-06 GB GB0225886A patent/GB2391476B/en not_active Expired - Fee Related
- 2002-11-06 DE DE10262193.4A patent/DE10262193B4/de not_active Expired - Fee Related
- 2002-11-06 DE DE10251709A patent/DE10251709C5/de not_active Expired - Fee Related
- 2002-11-25 US US10/308,259 patent/US20040091493A1/en not_active Abandoned
- 2002-12-07 KR KR1020020077561A patent/KR100697360B1/ko active IP Right Grant
-
2003
- 2003-01-15 JP JP2003006735A patent/JP4824901B2/ja not_active Expired - Fee Related
-
2007
- 2007-08-09 JP JP2007208376A patent/JP5226257B2/ja not_active Expired - Fee Related
-
2012
- 2012-09-10 JP JP2012198441A patent/JP2012250992A/ja active Pending
-
2016
- 2016-08-26 US US15/248,195 patent/US20160361250A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102524684B1 (ko) * | 2022-09-05 | 2023-04-21 | 주식회사 래디안 | 피부의 방어 기능을 증진시키는 화장료 조성물 |
Also Published As
Publication number | Publication date |
---|---|
US20160361250A1 (en) | 2016-12-15 |
FR2843125B1 (fr) | 2012-11-16 |
JP5226257B2 (ja) | 2013-07-03 |
GB2391476A (en) | 2004-02-11 |
US20040091493A1 (en) | 2004-05-13 |
JP2004067660A (ja) | 2004-03-04 |
GB2391476B (en) | 2006-12-20 |
DE10251709B4 (de) | 2008-11-27 |
FR2843125A1 (fr) | 2004-02-06 |
JP2012250992A (ja) | 2012-12-20 |
JP2008019264A (ja) | 2008-01-31 |
DE10251709A1 (de) | 2004-02-12 |
JP4824901B2 (ja) | 2011-11-30 |
KR100697360B1 (ko) | 2007-03-20 |
DE10262193B4 (de) | 2019-06-27 |
GB0225886D0 (en) | 2002-12-11 |
DE10251709C5 (de) | 2011-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100697360B1 (ko) | 인간 유래 β-디펜신 타입 2 및/또는 타입 3의 유도활성성분 및 상기 활성성분을 포함하는 화장품 또는약학적 조성물 | |
FR2863893A1 (fr) | Utilisation de principes actifs stimulant les beta-defensines humaines de type 2 et/ou de type 3 | |
CA2386273C (en) | Cosmetic preparation of active substances with a synergistically increased radical protection factor | |
JP6615609B2 (ja) | 抗菌ペプチダーゼの合成を活性化する活性剤としての亜麻仁抽出物の使用 | |
US11311596B2 (en) | Active ingredient obtained from Ophiopogon japonicus for the treatment of atopic dermatitis | |
US20170112737A1 (en) | Cosmetics and pharmaceutical applications of gallic acid and gallic acid derivatives | |
JP2010514774A (ja) | 肌の状態および外観を改善するための組成物およびその使用方法 | |
FR2916634A1 (fr) | Association synergique vis-a-vis de la flore microbienne de l'epiderme humain et applications cosmetiques et pharmaceutiques | |
EP3033072B1 (en) | Reaction platform and method for making pollen based materials in combination with beeswax and uses thereof | |
KR101405558B1 (ko) | 카페오일알파네오엔돌핀 펩타이드 유도체 및 이의 항가려움 및 항아토피 소재로의 활용 | |
KR102215798B1 (ko) | 항균 펩타이드를 포함하는 보존제 및 이를 이용한 화장료 조성물 | |
DE102007024679A9 (de) | Verwendung von kosmetisch aktiven Wirkstoffen zum Schützen von FGF-2 | |
US20200061126A1 (en) | Reaction platform and method for making pollen based materials and uses thereof | |
WO2019150263A1 (en) | Reaction platform and method for making pollen based materials and uses thereof | |
KR102264354B1 (ko) | 피부 상태 개선용 조성물 | |
US20230092216A1 (en) | Active principle comprising a particular extract of punica granatum and uses for preventing and/or treating acne | |
Rezvani et al. | Evaluation of the effect of Kandovan propolis against Streptococcus Mutans | |
KR101379460B1 (ko) | 감태(Ecklonia cava )유래 마이톨과 fucoidan의 혼합물을 유효성분으로 함유하는 아토피 피부염 개선용 화장료 조성물 | |
JP7503503B2 (ja) | 炎症性成分を有する皮膚または粘膜の罹患を予防および処置するための化合物 | |
JP2001253830A (ja) | ヒアルロニダーゼ阻害剤 | |
Yossef et al. | Histological study of the effect of propolis on gingival tissue of albino rat | |
KR20230043873A (ko) | 다당류가 풍부한 봄박스 코스타툼 꽃 추출물 | |
EP4380599A1 (en) | Composition for the prevention and/or treatment of acne | |
JPH04279510A (ja) | 活性酸素抑制剤 | |
NZ628601B (en) | Reaction platform and method for making pollen based materials in combination with beeswax and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130304 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140226 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150310 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160308 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170303 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180222 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190307 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20200226 Year of fee payment: 14 |